Biopharmaceutical Analysis eBook
Read the article:
Prioritizing Cleaning Validation
Read the eBook
BioPharm International’s Biopharmaceutical Analysis eBook
As recent COVID-19 vaccine facility citations make clear, failure to meet cleaning and sanitization requirements puts patients, facilities, and operators at risk.
bankrx - Stock.adobe.com
While the importance of cleaning procedures in bio/pharmaceutical facilities are well-known, recent regulatory citations suggest that pharmaceutical manufacturers and contract manufacturing and development organizations (CDMOs) may take cleaning and cleaning validation for granted. Multiproduct facilities, and particularly biopharmaceutical facilities, pose several cleaning validation challenges.
Read the article:
Prioritizing Cleaning Validation
Read the eBook
BioPharm International’s Biopharmaceutical Analysis eBook
Risk-based standards for cleaning validation, established in recent years, have established a more scientific basis for cleaning practices. Taking cleaning and sanitization validation programs for granted, however, puts facilities and people at risk and increases the likelihood of costly noncompliance.
Read this article in BioPharm International’s July 2021 Biopharmaceutical Analysis eBook.
Agnes Shanley is former senior editor to BioPharm International.
BioPharm International
eBook: Biopharmaceutical Analysis, July 2021
July 2021
Pages: 35–37
When referring to this article, please cite it as A. Shanley, “Prioritizing Cleaning Validation," BioPharm International Biopharmaceutical Analysis eBook (July 2021).
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.